Literature DB >> 31350640

Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.

Charlotte Rastas1, David Sirignano2, Amanda Barner2, Lou Ann Bruno-Murtha3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31350640     DOI： 10.1007/s00415-019-09483-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

Review 1.  Microbiology and Epidemiology of Legionnaire's Disease.

Authors:  Almudena Burillo; María Luisa Pedro-Botet; Emilio Bouza
Journal:  Infect Dis Clin North Am       Date:  2017-03       Impact factor: 5.982

Review 2.  Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Alexander Rae-Grant; Gregory S Day; Ruth Ann Marrie; Alejandro Rabinstein; Bruce A C Cree; Gary S Gronseth; Michael Haboubi; June Halper; Jonathan P Hosey; David E Jones; Robert Lisak; Daniel Pelletier; Sonja Potrebic; Cynthia Sitcov; Rick Sommers; Julie Stachowiak; Thomas S D Getchius; Shannon A Merillat; Tamara Pringsheim
Journal:  Neurology       Date:  2018-04-24       Impact factor: 9.910

3.  The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.

Authors:  Bhupendra O Khatri; Jeffery Garland; Joseph Berger; John Kramer; Lisa Sershon; Tayo Olapo; Jean Sesing; Mary Dukic; Eileen Rehn
Journal:  Mult Scler Relat Disord       Date:  2015-05-14       Impact factor: 4.339

4.  Increased sensitivity of a direct fluorescent antibody test for Legionella pneumophila in bronchoalveolar lavage samples by immunomagnetic separation based on BioMags.

Authors:  Shneh Sethi; Mitchell T Gore; Krishan K Sethi
Journal:  J Microbiol Methods       Date:  2007-05-21       Impact factor: 2.363

Review 5.  Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.

Authors:  David J Epstein; Jeffrey Dunn; Stan Deresinski
Journal:  Open Forum Infect Dis       Date:  2018-07-16       Impact factor: 3.835

6.  Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Authors:  Ludwig Kappos; Ralf Gold; David H Miller; David G Macmanus; Eva Havrdova; Volker Limmroth; Chris H Polman; Klaus Schmierer; Tarek A Yousry; Minhua Yang; Mefkûre Eraksoy; Eva Meluzinova; Ivan Rektor; Katherine T Dawson; Alfred W Sandrock; Gilmore N O'Neill
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

Review 7.  Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

Authors:  Irene Tramacere; Cinzia Del Giovane; Georgia Salanti; Roberto D'Amico; Graziella Filippini
Journal:  Cochrane Database Syst Rev       Date:  2015-09-18

Review 8.  Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.

Authors:  Elizabeth A Mills; Magdalena A Ogrodnik; Andrew Plave; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2018-01-23       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.